ProQR Therapeutics N.V. (NASDAQ:PRQR) has a beta value of 0.19 and has seen 3.0 million shares traded in the last trading session. The company, currently valued at $183.81M, closed the last trade at $2.63 per share which meant it lost -$0.18 on the day or -6.41% during that session. The PRQR stock price is -133.84% off its 52-week high price of $6.15 and 79.85% above the 52-week low of $0.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.79 million shares traded. The 3-month trading volume is 2.90 million shares.
The consensus among analysts is that ProQR Therapeutics N.V. (PRQR) is an Overweight stock at the moment, with a recommendation rating of 2.40. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 4 out of 8 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.21.
ProQR Therapeutics N.V. (NASDAQ:PRQR) trade information
Sporting -6.41% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the PRQR stock price touched $2.63 or saw a rise of 27.15%. Year-to-date, ProQR Therapeutics N.V. shares have moved -28.92%, while the 5-day performance has seen it change -23.32%. Over the past 30 days, the shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have changed 62.35%. Short interest in the company has seen 1.25 million shares shorted with days to cover at 2.35.
Wall Street analysts have a consensus price target for the stock at $3.27, which means that the shares’ value could jump 19.57% from current levels. The projected low price target is $0.94 while the price target rests at a high of $5.00. In that case, then, we find that the current price level is -90.11% off the targeted high while a plunge would see the stock lose 64.26% from current levels.
ProQR Therapeutics N.V. (PRQR) estimates and forecasts
Figures show that ProQR Therapeutics N.V. shares have outperformed across the wider relevant industry. The company’s shares have gained 230.82% over the past 6 months, with this year growth rate of 14.91%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 16.00% and 32.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be 48.60%.
6 analysts offering their estimates for the company have set an average revenue estimate of $850k for the current quarter. 6 have an estimated revenue figure of $850k for the next quarter concluding in Dec 2022.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.50% over the past 5 years.
ProQR Therapeutics N.V. is expected to release its next earnings report between February 22 and February 27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ProQR Therapeutics N.V. (NASDAQ:PRQR)’s Major holders
Insiders own 7.77% of the company shares, while shares held by institutions stand at 43.60% with a share float percentage of 47.28%. Investors are also buoyed by the number of investors in a company, with ProQR Therapeutics N.V. having a total of 72 institutions that hold shares in the company. The top two institutional holders are Privium Fund Management B.V. with over 5.34 million shares worth more than $4.16 million. As of Jun 29, 2022, Privium Fund Management B.V. held 7.50% of shares outstanding.
The other major institutional holder is Adage Capital Partners GP L.L.C., with the holding of over 3.3 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $2.57 million and represent 4.63% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and iShares NASDAQ Biotechnology ETF. As of Jun 29, 2022, the former fund manager holds about 0.87% shares in the company for having 0.62 million shares of worth $0.48 million while later fund manager owns 0.45 million shares of worth $0.34 million as of Sep 29, 2022, which makes it owner of about 0.63% of company’s outstanding stock.